glp 1 non diabetic GLP-1-based therapies for diabetes, obesity and beyond GLP-1 Drug Savings: A Complete

(Hurley & Frier, 2025) For patients, this means the first question to ask of any provider offering peptide therapy isn't "do you offer peptides" but "how are you sourcing them and what is the current regulatory status of each compound you prescribe?" A provider still listing Category 2 compounds as standard menu offerings without discussing compounding compliance is telling you something important about their regulatory literacy

Both are on the July 2026 Pharmacy Compounding Advisory Committee agenda for 503A compounding review, which is a separate regulatory question from approval

Clean sourcing and good technique protect the process, while sound habits amplify the signal

Nature 645, 712721 (2025)